Marc de Garidel is a graduate from the French Engineering School ESTP and has an Executive MBA from Harvard Business School.
Marc de Garidel started his career with Eli Lilly with various responsibilities in countries like US, Germany, France. Between 1995 and 2010, he held Executive position in finance & general management including the biggest region of Amgen International operations & the corporate controller of Amgen Inc.
Marc de Garidel joined Ipsen as Chairman and CEO in November 2010.
He is now Chairman of the Board of Directors of Ipsen since the third quarter of 2016 and is advisor of the Ipsen holding company Mayroy SA.
Marc de Garidel has been CEO of Corvidia Therapeutics, Inc. since March 29, 2018.